Skip to content
← Clinical Cases

Human Immunodeficiency Virus (HIV) — clinical cases

30 questions

Sample cases

  1. Case 1

    A 34-year-old man is newly diagnosed with HIV. He has no other medical conditions and takes no medications. HIV RNA is 85,000 copies/mL, CD4 count 420 cells/mm3, HBsAg negative, creatinine 80 µmol/L (0.9 mg/dL). He has never used PrEP. The team wants to start ART today, before genotype results are back. Which regimen is most appropriate?

    • A.Bictegravir/emtricitabine/tenofovir alafenamide once daily
    • B.Efavirenz/emtricitabine/tenofovir disoproxil fumarate once daily
    • C.Rilpivirine/emtricitabine/tenofovir alafenamide once daily with a meal
    • D.Dolutegravir/rilpivirine once daily with a meal
  2. Case 2

    A 41-year-old woman is newly diagnosed with HIV. Baseline tests: HBsAg positive, HBV DNA 2.1 × 105 IU/mL, HIV RNA 60,000 copies/mL, CD4 380 cells/mm3, eGFR 95 mL/min/1.73 m2. HLA-B*5701 negative. Which initial regimen is most appropriate?

    • A.Dolutegravir/lamivudine, with HBV DNA checked every 3 months
    • B.Dolutegravir plus tenofovir alafenamide/emtricitabine
    • C.Dolutegravir/abacavir/lamivudine as a single-tablet regimen
    • D.Dolutegravir/rilpivirine as a once-daily two-drug tablet
  3. Case 3

    A 29-year-old man with newly diagnosed HIV has a positive HLA-B*5701 test. Which actions are appropriate? Select ALL that apply.

    • A.Record abacavir hypersensitivity as an allergy in his medical record
    • B.Avoid all abacavir-containing products, including dolutegravir/abacavir/lamivudine
    • C.Start abacavir with antihistamine premedication and close monitoring
    • D.Repeat the HLA-B*5701 test in 6 months before deciding on abacavir
    • E.Use a non-abacavir regimen such as bictegravir/emtricitabine/tenofovir alafenamide